BeiGene
BeiGene Ltd is a global biotechnology company engaged in the discovery, clinical development, and commercialization of innovative oncology therapeutics. The company specializes in targeted small molecule therapies and immuno-oncology agents designed to treat hematologic malignancies and solid tumors. Its core product portfolio features the proprietary BTK inhibitor Brukinsa and the anti-PD-1 antibody Tevimbra, alongside licensed commercial oncology products. Primary revenues stem from worldwide commercial sales of its flagship cancer medicines, with major geographic end markets in the United States, China, and Europe. The enterprise occupies a prominent position in global oncology innovation due to its extensive clinical development infrastructure and commercial reach. BeiGene Ltd maintaining operational headquarters in Beijing, China, and trades publicly on the Nasdaq Global Select Market, the Hong Kong Stock Exchange, and the Shanghai Stock Exchange.
33 of the funds FundTelligence covers report a position in BeiGene.
- Legal name
- BeiGene Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 33
Funds holding BeiGene
- HealthInvest Small & Mid Cap Healthcare — HealthInvest · 4.9 % (partially disclosed portfolio, September 2026)
- Schroder ISF BIC (Brazil India China) — Schroders · 3.16 % (largest positions only, October 2026)
- HealthInvest Sustainable Healthcare — HealthInvest · 1.9 % (partially disclosed portfolio, September 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 1.56 % (full portfolio disclosed, September 2026)
- BNP China Equity — BNP Paribas · 1.49 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.94 % (full portfolio disclosed, October 2026)
- DNB Fund Brighter Future — DNB · 0.83 % (full portfolio disclosed, August 2026)
- DNB Global Emerging Markets — DNB · 0.78 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 33 funds holding it.